CNBX Pharmaceuticals Inc.

Equities

CNBX

US13764M2098

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 11:56:56 28/05/2024 pm IST			5-day change	1st Jan Change
0.0089 ^USD	-9.18%		-3.26%	-37.32%

16/04	CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
12/01	CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	CI

Cannabics Pharmaceuticals Inc. Announces Resignation of Ehud Reiger and Eyal Ballan as Directors

October 12, 2019 at 01:42 am IST

On October 7, 2019, Ehud Reiger and Eyal Ballan resigned from their positions as Directors and Board Members of the Cannabics Pharmaceuticals Inc. Eyal Ballan remains as the Chief Technical Officer of the Company.

Latest news about CNBX Pharmaceuticals Inc.

CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	16/04	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	12/01	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	30/11	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	14/23/14	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	14/23/14	CI
CNBX Pharmaceuticals Inc. Announces Board Resignations	08/23/08	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	13/23/13	CI
Shaul Yemal Resigns Position as Director and Board Member Cnbx Pharmaceuticals Inc	30/22/30	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2022	30/22/30	CI
CNBX Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	30/22/30	CI
CNBX Pharmaceuticals Inc. acquired unknown stake in TaGeza Biopharmaceuticals Ltd.	08/22/08	CI
CNBX Pharmaceuticals Inc. Announces That the Company Has Filed A New Patent Application Titled " Compositions Comprising Cannabinoids and Methods of Use Thereof in the Treatment of Cancer" Under the Patent Cooperation Treaty	18/22/18	CI
CNBX Pharmaceuticals Inc. Announces Executive Changes	25/22/25	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022	14/22/14	CI
CNBX Pharmaceuticals Inc. Receives Grant of Patent Notice by the Patent Registry, Intellectual Property Department, the Government of the Hong Kong Special Administrative Region	05/22/05	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2022	12/22/12	CI
Cannabics Pharmaceuticals Inc. has Changed its Name to CNBX Pharmaceuticals Inc	28/22/28	CI
Cannabics Pharmaceuticals Inc. Enters into Forbearance Agreement with an Institutional Investor	17/22/17	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2021	13/22/13	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2021	30/21/30	CI
CNBX Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	29/21/29	CI
Cannabics Pharmaceuticals Inc. Appoints Shaul Yemal as an Independent Director and as A Member of the Audit Committee	20/21/20	CI
Cannabics Pharmaceuticals Inc. Appoints Yonina Tova to Board of Advisors	25/21/25	CI
Cannabics Pharmaceuticals Inc. Files 2 Provisional Patents on Compositions and Methods for Treating Cancer	18/21/18	CI
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine	13/21/13	CI

Chart CNBX Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

CNBX Pharmaceuticals Inc. is a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CNBX PHARMACEUTICALS INC.	-37.32%	3L
VERTEX PHARMACEUTICALS INCORPORATED	+9.86%	12TCr
REGENERON PHARMACEUTICALS, INC.	+9.93%	11TCr
BIONTECH SE	-11.18%	2.34TCr
ARGENX SE	-1.69%	2.21TCr
GENMAB A/S	-10.23%	1.83TCr
WUXI APPTEC CO., LTD.	-41.92%	1.66TCr
BEIGENE, LTD.	-15.59%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+6.69%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+16.32%	1.17TCr

Bio Therapeutic Drugs